Safety of vaccines used for routine immunization of US children: A systematic review

Pediatrics

Volumn 134, Issue 2, 2014, Pages 325-337

  Maglione, Margaret A ^a   Das, Lopamudra ^a   Raaen, Laura ^a   Smith, Alexandria ^a   Chari, Ramya ^a   Newberry, Sydne ^a   Shanman, Roberta ^a   Perry, Tanja ^a   Goetz, Matthew Bidwell ^b   Gidengil, Courtney ^a,c  

^a RAND CORPORATION   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Evidence based medicine; Infectious disease; Vaccine immunization

Indexed keywords

BACTERIAL VACCINE; CHICKENPOX VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; MEASLES MUMPS RUBELLA VACCINE; MENINGOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; ROTAVIRUS VACCINE; VIRUS VACCINE; WART VIRUS VACCINE;

ANAPHYLAXIS; AUTISM; BACTERIAL INFECTION; CHICKENPOX; CHILD; CHILD HEALTH CARE; CONSENSUS; CONVULSION; DIARRHEA; DIPHTHERIA; DISEASE SEVERITY; DRUG SAFETY; DRUG USE; EVIDENCE BASED MEDICINE; FEBRILE CONVULSION; FLU LIKE SYNDROME; GASTROESOPHAGEAL REFLUX; HEALTH SURVEY; HEPATITIS A; HEPATITIS B; HUMAN; IMMUNE DEFICIENCY; IMMUNIZATION; INFLUENZA; INTUSSUSCEPTION; MCHARM SCALE; MEASLES; MENINGOCOCCOSIS; MUMPS; MYCOSIS; PAPILLOMAVIRUS INFECTION; PERTUSSIS; PNEUMOCOCCAL INFECTION; POLIOMYELITIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RATING SCALE; REVIEW; RISK ASSESSMENT; RISK FACTOR; ROTAVIRUS INFECTION; RUBELLA; SYSTEMATIC REVIEW; TETANUS; UNITED STATES; VIRUS INFECTION; VOMITING;

EVIDENCE-BASED MEDICINE; INFECTIOUS DISEASE; VACCINE/IMMUNIZATION;

CHICKENPOX VACCINE; CHILD; HUMANS; IMMUNIZATION; MEASLES-MUMPS-RUBELLA VACCINE; PATIENT SAFETY; POPULATION SURVEILLANCE; ROTAVIRUS VACCINES; UNITED STATES; VACCINES; VIRAL HEPATITIS VACCINES;

EID: 84903732887     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2014-1079     Document Type: Review

References (97)

1. Centers for Disease Control and Prevention (CDC). Ten great public health achievements - United States, 1900-1999. MMWR Morb Mortal Wkly Rep. 1999;48(12):241-243
2. Sugerman DE, Barskey AE, Delea MG, et al. Measles outbreak in a highly vaccinated population, San Diego, 2008: role of the intentionally undervaccinated. Pediatrics. 2010;125(4):747-755
3. Atwell JE, Van Otterloo J, Zipprich J, et al. Nonmedical vaccine exemptions and pertussis in California, 2010. Pediatrics. 2013;132(4):624-630
4. Institute of Medicine. Adverse Effects of Vaccines: Evidence and Causality. Washington, DC: The National Academy Press; 2011
5. Castro M, Dozor A, Fish J, et al. The safety of inactivated influenza vaccine in adults and children with asthma. N Engl J Med. 2001;345(21):1529-1536 (Pubitemid 33144918)
6. US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. May 28, 2009 (v4.03: June 14, 2010)
7. Santaguida PL, Raina P. The Development of the McHarm Quality Assessment Scale for adverse events: Delphi Consensus on important criteria for evaluating harms. 2008. Available at: http://hiru.mcmaster.ca/epc/mcharm.pdf. Accessed May 5, 2012
8. Owens DK, Lohr KN, Atkins D, et al. AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions - agency for healthcare research and quality and the effective health-care program. J Clin Epidemiol. 2010;63(5):513-523
9. Balshem H, Helfand M, Schünemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64(4):401-406
10. Blom L, Nyström L, Dahlquist G. The Swedish childhood diabetes study. Vaccinations and infections as risk determinants for diabetes in childhood. Diabetologia. 1991;34(3):176-181
11. DeStefano F, Mullooly JP, Okoro CA, et al Vaccine Safety Datalink Team. Childhood vaccinations, vaccination timing, and risk of type 1 diabetes mellitus. Pediatrics. 2001;108(6):E112
12. Hviid A, Stellfeld M, Wohlfahrt J, Melbye M. Childhood vaccination and type 1 diabetes. N Engl J Med. 2004;350(14):1398-1404 (Pubitemid 38419993)
13. Klein NP, Hansen J, Lewis E, et al. Post-marketing safety evaluation of a tetanus toxoid, reduced diphtheria toxoid and 3-component acellular pertussis vaccine administered to a cohort of adolescents in a United States health maintenance organization. Pediatr Infect Dis J. 2010;29(7):613-617
14. Infections and vaccinations as risk factors for childhood type I (insulin-dependent) diabetes mellitus: a multicentre case-control investigation. EURODIAB Substudy 2 Study Group. Diabetologia. 2000;43(1):47-53
15. Huu TN, Toan NT, Tuan HM, et al. Safety and reactogenicity of primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Vietnamese infants: a randomised, controlled trial. BMC Infect Dis. 2013;13:95
16. Santosham M, Wolff M, Reid R, et al. The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex. N Engl J Med. 1991;324(25):1767-1772
17. Capeding MRZ, Nohynek H, Pascual LG, et al. The immunogenicity of three Haemophilus influenzae type B conjugate vaccines after a primary vaccination series in Philippine infants. Am J Trop Med Hygiene. 1996;55(5):516-520 (Pubitemid 26392715)
18. O'Leary ST, Glanz JM, McClure DL, et al. The risk of immune thrombocytopenic purpura after vaccination in children and adolescents. Pediatrics. 2012;129(2):248-255
19. Institute of Medicine. Immunization Safety Review: Multiple Immunizations and Immune Dysfunction. Washington, DC: The National Academies Press; 2002
20. Gallagher CM, Goodman MS. Hepatitis B vaccination of male neonates and autism diagnosis, NHIS 1997-2002. J Toxicol Environ Health A. 2010;73(24):1665-1677
21. Grüber C, Warner J, Hill D, Bauchau V; EPAAC Study Group. Early atopic disease and early childhood immunization - is there a link? Allergy. 2008;63(11):1464-1472
22. Mullooly JP, Schuler R, Barrett M, Maher JE. Vaccines, antibiotics, and atopy. Pharmacoepidemiol Drug Saf. 2007;16(3):275-288 (Pubitemid 46431690)
23. Englund JA, Walter E, Black S, et al; GRC28 Study Team. Safety and immunogenicity of trivalent inactivated influenza vaccine in infants: a randomized double-blind placebo-controlled study. Pediatr Infect Dis J. 2010;29(2):105-110
24. Mallory RM, Malkin E, Ambrose CS, et al. Safety and immunogenicity following administration of a live, attenuated monovalent 2009 H1N1 influenza vaccine to children and adults in two randomized controlled trials. PLoS ONE. 2010;5(10):e13755
25. Stowe J, Andrews N, Bryan P, Seabroke S, Miller E. Risk of convulsions in children after monovalent H1N1 (2009) and trivalent influenza vaccines: a database study. Vaccine. 2011;29(51):9467-9472
26. Tse A, Tseng HF, Greene SK, Vellozzi C, Lee GM; VSD Rapid Cycle Analysis Influenza Working Group. Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010-2011. Vaccine. 2012;30(11):2024- 2031
27. Baxter R, Toback SL, Sifakis F, et al. A postmarketing evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in children 5 through 17 years of age. Vaccine. 2012;30(19):2989-2998
28. Glanz JM, Newcomer SR, Hambidge SJ, et al. Safety of trivalent inactivated influenza vaccine in children aged 24 to 59 months in the vaccine safety datalink. Arch Pediatr Adolesc Med. 2011;165(8):749-755
29. Morgan TM, Schlegel C, Edwards KM, et al Urea Cycle Disorders Consortium. Vaccines are not associated with metabolic events in children with urea cycle disorders. Pediatrics. 2011;127(5). Available at: www.pediatrics.org/cgi/ content/full/127/5/e1147
30. Hambidge SJ, Ross C, McClure D, Glanz J; VSD team. Trivalent inactivated influenza vaccine is not associated with sickle cell hospitalizations in adults from a large cohort. Vaccine. 2011;29(46):8179-8181
31. Italian Multicenter Study Group for Drug and Vaccine Safety in Children. Effectiveness and safety of the A-H1N1 vaccine in children: a hospital-based case-control study. BMJ Open. 2011;1(2):e000167
32. Barlow WE, Davis RL, Glasser JW, et al Centers for Disease Control and Prevention Vaccine Safety Datalink Working Group. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. N Engl J Med. 2001;345(9):656-661
33. Chen RT, Glasser JW, Rhodes PH, et al The Vaccine Safety Datalink Team. Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States. Pediatrics. 1997;99(6):765-773 (Pubitemid 27231345)
34. Farrington P, Pugh S, Colville A, et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet. 1995;345(8949):567-569
35. Griffin MR, Ray WA, Mortimer EA, Fenichel GM, Schaffner W. Risk of seizures after measles-mumps-rubella immunization. Pediatrics. 1991;88(5):881-885
36. Miller E, Andrews N, Stowe J, Grant A, Waight P, Taylor B. Risks of convulsion and aseptic meningitis following measles-mumps-rubella vaccination in the United Kingdom. Am J Epidemiol. 2007;165(6):704-709 (Pubitemid 46348369)
37. Vestergaard M, Hviid A, Madsen KM, et al. MMR vaccination and febrile seizures: evaluation of susceptible subgroups and long-term prognosis. JAMA. 2004;292(3):351-357 (Pubitemid 38944259)
38. Ward KN, Bryant NJ, Andrews NJ, et al. Risk of serious neurologic disease after immunization of young children in Britain and Ireland. Pediatrics. 2007;120(2):314-321 (Pubitemid 47219501)
39. Benjamin CM, Chew GC, Silman AJ. Joint and limb symptoms in children after immunisation with measles, mumps, and rubella vaccine. BMJ. 1992;304(6834):1075-1078
40. Davis RL, Marcuse E, Black S, et al The Vaccine Safety Datalink Team. MMR2 immunization at 4 to 5 years and 10 to 12 years of age: a comparison of adverse clinical events after immunization in the Vaccine Safety Datalink project. Pediatrics. 1997;100(5):767-771 (Pubitemid 27463311)
41. Dos Santos BA, Ranieri TS, Bercini M, et al. An evaluation of the adverse reaction potential of three measles-mumps-rubella combination vaccines. Rev Panam Salud Publica. 2002;12(4):240-246 (Pubitemid 35283052)
42. Heijstek MW, Pileggi GC, Zonneveld-Huijssoon E, et al. Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis. Ann Rheum Dis. 2007;66(10):1384-1387 (Pubitemid 47492487)
43. LeBaron CW, Bi D, Sullivan BJ, Beck C, Gargiullo P. Evaluation of potentially common adverse events associated with the first and second doses of measles-mumps-rubella vaccine. Pediatrics. 2006;118(4):1422-1430 (Pubitemid 46393787)
44. Peltola H, Heinonen OP. Frequency of true adverse reactions to measles-mumps-rubella vaccine. A double-blind placebo-controlled trial in twins. Lancet. 1986;1(8487):939-942 (Pubitemid 16143073)
45. Virtanen M, Peltola H, Paunio M, Heinonen OP. Day-to-day reactogenicity and the healthy vaccinee effect of measles-mumps-rubella vaccination. Pediatrics. 2000;106(5). Available at: www.pediatrics.org/cgi/content/full/106/ 5/e62
46. Farrington CP, Miller E, Taylor B. MMR and autism: further evidence against a causal association. Vaccine. 2001;19(27):3632-3635 (Pubitemid 32522760)
47. Madsen KM, Hviid A, Vestergaard M, et al. A population-based study of measles, mumps, and rubella vaccination and autism. N Engl J Med. 2002;347(19):1477-1482 (Pubitemid 35257586)
48. Mrozek-Budzyn D, Kiełtyka A, Majewska R. Lack of association between measles-mumps-rubella vaccination and autism in children: a case-control study. Pediatr Infect Dis J. 2010;29(5):397-400
49. Smeeth L, Cook C, Fombonne E, et al. MMR vaccination and pervasive developmental disorders: a case-control study. Lancet. 2004;364(9438):963-969 (Pubitemid 39208457)
50. Taylor B, Miller E, Farrington CP, et al. Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association. Lancet. 1999;353(9169):2026-2029 (Pubitemid 29271747)
51. Uno Y, Uchiyama T, Kurosawa M, Aleksic B, Ozaki N. The combined measles, mumps, and rubella vaccines and the total number of vaccines are not associated with development of autism spectrum disorder: the first case-control study in Asia. Vaccine. 2012;30(28):4292-4298
52. Andrews N, Stowe J, Miller E, et al; VAESCO consortium. A collaborative approach to investigating the risk of thrombocytopenic purpura after measles-mumps-rubella vaccination in England and Denmark. Vaccine. 2012;30(19):3042-3046
53. Bertuola F, Morando C, Menniti-Ippolito F, et al. Association between drug and vaccine use and acute immune thrombocytopenia in childhood: a case-control study in Italy. Drug Saf. 2010;33(1):65-72
54. Khalil M, Al-Mazrou Y, Findlow H, et al. Safety and immunogenicity of a meningococcal quadrivalent conjugate vaccine in five- to eight-year-old Saudi Arabian children previously vaccinated with two doses of a meningococcal quadrivalent polysaccharide vaccine. Clin Vaccine Immunol. 2012;19(10):1561-1566
55. Klein NP, Reisinger KS, Johnston W, et al. Safety and immunogenicity of a novel quadrivalent meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infants [published correction appears in Pediatr Infect Dis J. 2012;31(10):1105]. Pediatr Infect Dis J. 2012;31(1):64-71
56. Block SL, Vesikari T, Goveia MG, et al Pentavalent Rotavirus Vaccine Dose Confirmation Efficacy Study Group. Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life. Pediatrics. 2007;119(1):11-18 (Pubitemid 46397837)
57. Chang C-C, Chang M-H, Lin T-Y, Lee H-C, Hsieh W-S, Lee P-I. Experience of pentavalent human-bovine reassortant rotavirus vaccine among healthy infants in Taiwan. J Formos Med Assoc. 2009;108(4):280-285
58. Christie CDC, Duncan ND, Thame KA, et al. Pentavalent rotavirus vaccine in developing countries: safety and health care resource utilization. Pediatrics. 2010;126(6). Available at: www.pediatrics.org/cgi/content/full/126/ 6/e1499
59. Dennehy PH, Brady RC, Halperin SA, et al North American Human Rotavirus Vaccine Study Group. Comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine. Pediatr Infect Dis J. 2005;24(6):481-488 (Pubitemid 40847519)
60. Goveia MG, Rodriguez ZM, Dallas MJ, et al REST Study Team. Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants. Pediatr Infect Dis J. 2007;26(12):1099-1104 (Pubitemid 350190940)
61. Grant LR, Watt JP, Weatherholtz RC, et al. Efficacy of a pentavalent human-bovine reassortant rotavirus vaccine against rotavirus gastroenteritis among American Indian children. Pediatr Infect Dis J. 2012;31(2):184-188
62. Kawamura N, Tokoeda Y, Oshima M, et al. Efficacy, safety and immunogenicity of RIX4414 in Japanese infants during the first two years of life. Vaccine. 2011;29(37):6335-6341
63. Kerdpanich A, Chokephaibulkit K, Watanaveeradej V, et al. Immunogenicity of a live-attenuated human rotavirus RIX4414 vaccine with or without buffering agent. Hum Vaccin. 2010;6(3):254-262
64. Kim DS, Lee TJ, Kang JH, et al. Immunogenicity and safety of a pentavalent humanbovine (WC3) reassortant rotavirus vaccine in healthy infants in Korea. Pediatr Infect Dis J. 2008;27(2):177-178
65. Kim JS, Bae CW, Lee KY, et al. Immunogenicity, reactogenicity and safety of a human rotavirus vaccine (RIX4414) in Korean infants: a randomized, double-blind, placebo-controlled, phase IV study. Hum Vaccin Immunother. 2012;8(6):806-812
66. Madhi SA, Cunliffe NA, Steele D, et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med. 2010;362(4):289-298
67. Narang A, Bose A, Pandit AN, et al. Immunogenicity, reactogenicity and safety of human rotavirus vaccine (RIX4414) in Indian infants. Hum Vaccin. 2009;5(6):414-419
68. Omenaca F, Sarlangue J, Szenborn L, et al; ROTA-054 Study Group. Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European Infants: a randomized phase IIIb study. Pediatr Infect Dis J. 2012;31(5):487-493
69. Phua KB, Quak SH, Lee BW, et al. Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants. J Infect Dis. 2005;192(suppl 1):S6-S16 (Pubitemid 41193096)
70. Phua KB, Lim FS, Lau YL, et al. Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: randomised, double-blind, controlled study. Vaccine. 2009;27(43):5936-5941
71. Phua KB, Lim FS, Lau YL, et al. Rotavirus vaccine RIX4414 efficacy sustained during the third year of life: A randomized clinical trial in an Asian population. Vaccine. 2012;30(30):4552-4557
72. Rodriguez ZM, Goveia MG, Stek JE, et al. Concomitant use of an oral live pentavalent human-bovine reassortant rotavirus vaccine with licensed parenteral pediatric vaccines in the United States. Pediatr Infect Dis J. 2007;26(3):221-227 (Pubitemid 46340768)
73. Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, et al Human Rotavirus Vaccine Study Group. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med. 2006;354(1):11-22 (Pubitemid 43048947)
74. Sow SO, Tapia M, Haidara FC, et al. Efficacy of the oral pentavalent rotavirus vaccine in Mali. Vaccine. 2012;30(suppl 1):A71-A78
75. Steele AD, Reynders J, Scholtz F, et al. Comparison of 2 different regimens for reactogenicity, safety, and immunogenicity of the live attenuated oral rotavirus vaccine RIX4414 coadministered with oral polio vaccine in South African infants. J Infect Dis. 2010;202(suppl):S93-S100
76. Steele AD, Madhi SA, Louw CE, et al. Safety, reactogenicity, and immunogenicity of human rotavirus vaccine RIX4414 in human immunodeficiency virus-positive infants in South Africa. Pediatr Infect Dis J. 2011;30(2):125-130
77. Tregnaghi MW, Abate HJ, Valencia A, et al; Rota-024 Study Group. Human rotavirus vaccine is highly efficacious when coadministered with routine expanded program of immunization vaccines including oral poliovirus vaccine in Latin America. Pediatr Infect Dis J. 2011;30(6):e103-e108
78. Vesikari T, Karvonen A, Puustinen L, et al. Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants. Pediatr Infect Dis J. 2004;23(10):937-943 (Pubitemid 40812781)
79. Vesikari T, Clark HF, Offit PA, et al. Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants. Vaccine. 2006;24(22):4821-4829 (Pubitemid 43776799)
80. Vesikari T, Matson DO, Dennehy P, et al; Rotavirus Ef ficacy and Safety Trial (REST) Study Team. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med. 2006;354(1):23-33 (Pubitemid 43048948)
81. Vesikari T, Karvonen A, Bouckenooghe A, Suryakiran PV, Smolenov I, Han HH. Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 oral suspension (liquid formulation) in Finnish infants. Vaccine. 2011;29(11):2079-2084
82. Vesikari T, Karvonen A, Korhonen T, et al. Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants. Vaccine. 2004;22(21-22):2836-2842 (Pubitemid 38900662)
83. Zaman K, Sack DA, Yunus M, et al. Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age. Vaccine. 2009;27(9):1333-1339
84. Zaman K, Dang DA, Victor JC, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;376(9741):615-623
85. Zaman K, Yunus M, El Arifeen S, et al. Methodology and lessons-learned from the efficacy clinical trial of the pentavalent rotavirus vaccine in Bangladesh. Vaccine. 2012;30(suppl 1):A94-A100
86. Buttery JP, Danchin MH, Lee KJ, et al PAEDS/APSU Study Group. Intussusception following rotavirus vaccine administration: post-marketing surveillance in the National Immunization Program in Australia. Vaccine. 2011;29(16):3061-3066
87. Velázquez FR, Colindres RE, Grajales C, et al. Postmarketing surveillance of intussusception following mass introduction of the attenuated human rotavirus vaccine in Mexico. Pediatr Infect Dis J. 2012;31(7):736-744
88. Patel MM, López-Collada VR, Bulhões MM, et al. Intussusception risk and health benefits of rotavirus vaccination in Mexico and Brazil. N Engl J Med. 2011;364(24):2283-2292
89. Shui IM, Baggs J, Patel M, et al. Risk of intussusception following administration of a pentavalent rotavirus vaccine in US infants. JAMA. 2012;307(6):598-604
90. Yih K, Lieu T, Kulldorff M, et al. Intussusception risk after rotavirus vaccination in U.S. infants. Mini-Sentinel Coordinating Center; June 2013. Available at: www.mini-sentinel.org/work-products/PRISM/Mini-Sentinel-PRISM- Rotavirus-and-intussusception-Report.pdf. Accessed June 30, 2013
91. Black S, Shinefield H, Ray P, et al. Post-marketing evaluation of the safety and effectiveness of varicella vaccine. Pediatr Infect Dis J. 1999;18(12):1041-1046
92. Donahue JG, Kieke BA, Yih WK, et al; Vaccine Safety DataLink Team. Varicella vaccination and ischemic stroke in children: is there an association? Pediatrics. 2009;123(2). Available at: www.pediatrics.org/cgi/content/full/123/ 2/e228
93. Groves FD, Gridley G, Wacholder S, et al. Infant vaccinations and risk of childhood acute lymphoblastic leukaemia in the USA. Br J Cancer. 1999;81(1):175-178 (Pubitemid 29415509)
94. Ma X, Does MB, Metayer C, Russo C, Wong A, Buffler PA. Vaccination history and risk of childhood leukaemia. Int J Epidemiol. 2005;34(5):1100-1109 (Pubitemid 41535557)
95. MacArthur AC, McBride ML, Spinelli JJ, Tamaro S, Gallagher RP, Theriault GP. Risk of childhood leukemia associated with vaccination, infection, and medication use in childhood: the Cross-Canada Childhood Leukemia Study. Am J Epidemiol. 2008;167(5):598-606 (Pubitemid 351323311)
96. Pagaoa MA, Okcu MF, Bondy ML, Scheurer ME. Associations between vaccination and childhood cancers in Texas regions. J Pediatr. 2011;158(6):996-1002
97. Haber P, Iskander J, Walton K, Campbell SR, Kohl KS. Internet-based reporting to the vaccine adverse event reporting system: a more timely and complete way for providers to support vaccine safety. Pediatrics. 2011;127(suppl 1):S39-S44